DK2809150T3 - Humaniserede mus, der udtrykker tungkæder indeholdende VL-domæner - Google Patents

Humaniserede mus, der udtrykker tungkæder indeholdende VL-domæner Download PDF

Info

Publication number
DK2809150T3
DK2809150T3 DK13704329T DK13704329T DK2809150T3 DK 2809150 T3 DK2809150 T3 DK 2809150T3 DK 13704329 T DK13704329 T DK 13704329T DK 13704329 T DK13704329 T DK 13704329T DK 2809150 T3 DK2809150 T3 DK 2809150T3
Authority
DK
Denmark
Prior art keywords
domains
heavy chains
chains containing
mice expressing
humanized mice
Prior art date
Application number
DK13704329T
Other languages
Danish (da)
English (en)
Inventor
Lynn Macdonald
Cagan Gurer
Karolina A Meagher
Sean Stevens
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK2809150T3 publication Critical patent/DK2809150T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Housing For Livestock And Birds (AREA)
  • Central Heating Systems (AREA)
DK13704329T 2012-02-01 2013-02-01 Humaniserede mus, der udtrykker tungkæder indeholdende VL-domæner DK2809150T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261593463P 2012-02-01 2012-02-01
US201261677538P 2012-07-31 2012-07-31
PCT/US2013/024295 WO2013116609A1 (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Publications (1)

Publication Number Publication Date
DK2809150T3 true DK2809150T3 (da) 2019-12-09

Family

ID=47714588

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13704329T DK2809150T3 (da) 2012-02-01 2013-02-01 Humaniserede mus, der udtrykker tungkæder indeholdende VL-domæner
DK19191081.9T DK3597038T3 (da) 2012-02-01 2013-02-01 Humaniserede gnavere, der udtrykker tungkæder indeholdende VL-domæner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19191081.9T DK3597038T3 (da) 2012-02-01 2013-02-01 Humaniserede gnavere, der udtrykker tungkæder indeholdende VL-domæner

Country Status (26)

Country Link
US (3) US20130212719A1 (cg-RX-API-DMAC7.html)
EP (3) EP2809150B1 (cg-RX-API-DMAC7.html)
JP (6) JP2015505477A (cg-RX-API-DMAC7.html)
KR (2) KR20140123983A (cg-RX-API-DMAC7.html)
CN (2) CN106117364B (cg-RX-API-DMAC7.html)
AU (3) AU2013204758B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014018843B1 (cg-RX-API-DMAC7.html)
CA (1) CA2863175A1 (cg-RX-API-DMAC7.html)
CY (2) CY1122419T1 (cg-RX-API-DMAC7.html)
DK (2) DK2809150T3 (cg-RX-API-DMAC7.html)
ES (2) ES2870703T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20192218T1 (cg-RX-API-DMAC7.html)
HU (2) HUE055610T2 (cg-RX-API-DMAC7.html)
IL (3) IL233827A0 (cg-RX-API-DMAC7.html)
LT (2) LT3597038T (cg-RX-API-DMAC7.html)
ME (1) ME03611B (cg-RX-API-DMAC7.html)
MX (2) MX373286B (cg-RX-API-DMAC7.html)
NZ (5) NZ793447A (cg-RX-API-DMAC7.html)
PL (2) PL3597038T3 (cg-RX-API-DMAC7.html)
PT (2) PT2809150T (cg-RX-API-DMAC7.html)
RS (2) RS59699B1 (cg-RX-API-DMAC7.html)
RU (2) RU2770016C2 (cg-RX-API-DMAC7.html)
SG (3) SG10201913428QA (cg-RX-API-DMAC7.html)
SI (2) SI3597038T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201900685T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013116609A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2288623B1 (en) * 2008-05-23 2013-07-10 Ablexis, LLC Method of generating single vl domain antibodies in transgenic animals
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP2517556B2 (en) 2009-07-08 2023-03-22 Kymab Limited Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
RS55495B1 (sr) 2010-08-02 2017-04-28 Regeneron Pharma Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
SI3865581T1 (sl) 2011-08-05 2024-12-31 Regeneron Pharmaceuticals, Inc. Miši s humanizirano univerzalno lahko verigo
CA2846319A1 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
PL2793567T3 (pl) 2011-12-20 2019-09-30 Regeneron Pharmaceuticals, Inc. Myszy z humanizowanym łańcuchem lekkim
PL3597038T3 (pl) * 2012-02-01 2021-11-08 Regeneron Pharmaceuticals, Inc. Humanizowane gryzonie wykazujące ekspresję łańcuchów ciężkich zawierających domeny vl
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
CN104540383B (zh) 2012-06-12 2017-08-29 瑞泽恩制药公司 具有受限制的免疫球蛋白重链基因座的人源化非人动物
WO2014130690A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
ES2872475T3 (es) 2014-03-21 2021-11-02 Regeneron Pharma Animales no humanos que producen proteínas de unión de dominio único
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
JP2018508224A (ja) * 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
WO2016161446A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
IL299000A (en) * 2016-04-04 2023-02-01 Eth Zuerich A mammalian cell line for protein production and a breeding library
AU2017268458B2 (en) 2016-05-20 2022-07-21 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide RNAS
CN110719732B (zh) * 2017-03-30 2022-11-18 犹他州立大学 表达蜘蛛丝的转基因蚕
PT3720279T (pt) * 2017-12-05 2022-10-06 Regeneron Pharma Ratinhos tendo uma cadeia leve lambda de imunoglobulina manipulada e seus usos
HUE070158T2 (hu) * 2018-03-24 2025-05-28 Regeneron Pharma Genetikailag módosított egerek vagy patkányok peptid-mhc komplexek elleni terápiás antitestek létrehozásra, ezek elõállítására szolgáló módszerek, valamint alkalmazásuk
IL318469A (en) * 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
CN116848254A (zh) 2020-12-16 2023-10-03 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
CN114645042A (zh) * 2020-12-18 2022-06-21 中国食品药品检定研究院 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法
CN114196626A (zh) * 2022-02-16 2022-03-18 北京国卫生物科技有限公司 脐带间充质干细胞及其分离培养扩增方法
CN118339300A (zh) * 2024-01-02 2024-07-12 江苏集萃药康生物科技股份有限公司 产生人源化抗体的动物模型及其构建方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
EP1311530A4 (en) * 2000-08-03 2004-10-06 Wim-Van Schooten PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
DE60239420D1 (de) 2001-12-21 2011-04-21 Thrombogenics Nv Zusammensetzungen für die in vitro herleitung und kultur embryonaler stammzellinien mit keimbahnübertragungsfähigkeit und für die kultur adulter stammzellen
WO2003081993A2 (en) * 2002-03-22 2003-10-09 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
CN103205436B (zh) * 2003-07-15 2016-05-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
PL1802193T3 (pl) 2004-10-19 2014-09-30 Regeneron Pharma Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej
WO2006047367A2 (en) * 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglubolin expression in non-human transgenic animals
EP2003960B1 (en) * 2006-03-31 2015-06-10 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
WO2008027986A2 (en) * 2006-09-01 2008-03-06 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
WO2009026660A1 (en) * 2007-08-30 2009-03-05 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
PH12021552811A1 (en) * 2007-09-26 2022-11-21 Chugai Pharmaceutical Co Ltd Modified antibody constant region
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
EP2288623B1 (en) * 2008-05-23 2013-07-10 Ablexis, LLC Method of generating single vl domain antibodies in transgenic animals
DK2556747T3 (da) * 2008-06-27 2021-02-15 Merus Nv Antistofproducerende transgen mus
MX2011001930A (es) * 2008-08-29 2011-04-21 Symphogen As Metodo para clonar anticuerpos derivados de aves.
CA2750520C (en) * 2009-02-04 2017-12-05 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
EP2517556B2 (en) * 2009-07-08 2023-03-22 Kymab Limited Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
SG186238A1 (en) * 2010-06-17 2013-01-30 Kymab Ltd Animal models and therapeutic molecules
RS55495B1 (sr) * 2010-08-02 2017-04-28 Regeneron Pharma Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
HRP20230526T1 (hr) * 2011-02-25 2023-09-01 Regeneron Pharmaceuticals, Inc. Adam6 miševi
SI3865581T1 (sl) * 2011-08-05 2024-12-31 Regeneron Pharmaceuticals, Inc. Miši s humanizirano univerzalno lahko verigo
PL2793567T3 (pl) * 2011-12-20 2019-09-30 Regeneron Pharmaceuticals, Inc. Myszy z humanizowanym łańcuchem lekkim
PL3597038T3 (pl) * 2012-02-01 2021-11-08 Regeneron Pharmaceuticals, Inc. Humanizowane gryzonie wykazujące ekspresję łańcuchów ciężkich zawierających domeny vl
CN104540383B (zh) * 2012-06-12 2017-08-29 瑞泽恩制药公司 具有受限制的免疫球蛋白重链基因座的人源化非人动物
PL3766343T3 (pl) * 2016-11-04 2022-09-26 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż człowiek posiadające zmodyfikowany sposobami inżynierii locus łańcucha lekkiego lambda immunoglobuliny

Also Published As

Publication number Publication date
JP7525579B2 (ja) 2024-07-30
EP3912465A1 (en) 2021-11-24
HRP20210987T1 (hr) 2021-09-17
PL2809150T3 (pl) 2020-04-30
JP2023168590A (ja) 2023-11-24
ES2870703T3 (es) 2021-10-27
EP2809150B1 (en) 2019-09-18
AU2013204758B2 (en) 2015-07-23
CN106117364B (zh) 2021-08-31
ME03611B (me) 2020-07-20
NZ719228A (en) 2022-08-26
RU2664185C2 (ru) 2018-08-15
PT3597038T (pt) 2021-05-10
HK1202771A1 (en) 2015-10-09
LT2809150T (lt) 2019-10-25
MX373286B (es) 2020-05-20
CN106117364A (zh) 2016-11-16
WO2013116609A1 (en) 2013-08-08
IL268675B (en) 2020-11-30
KR20140123983A (ko) 2014-10-23
JP2023014242A (ja) 2023-01-26
AU2015246154B2 (en) 2017-11-23
SG10201606256TA (en) 2016-09-29
BR112014018843B1 (pt) 2024-02-20
MX2020003491A (es) 2022-10-25
IL261280A (en) 2018-10-31
PL3597038T3 (pl) 2021-11-08
RU2014133653A (ru) 2016-03-20
NZ627977A (en) 2016-06-24
SMT202100401T1 (it) 2021-09-14
HUE046744T2 (hu) 2020-03-30
AU2015246154A1 (en) 2015-11-12
MX2019002517A (es) 2019-06-17
AU2013204758A1 (en) 2013-08-15
JP7187615B2 (ja) 2022-12-12
JP2019170395A (ja) 2019-10-10
AU2017251848B2 (en) 2020-02-20
RS62023B1 (sr) 2021-07-30
JP2018075041A (ja) 2018-05-17
ES2753774T3 (es) 2020-04-14
NZ734504A (en) 2022-10-28
SI3597038T1 (sl) 2021-07-30
EP3597038B1 (en) 2021-04-21
CY1122419T1 (el) 2021-01-27
CN104202971A (zh) 2014-12-10
SG10201913428QA (en) 2020-03-30
NZ810648A (en) 2025-11-28
JP6942757B2 (ja) 2021-09-29
HRP20192218T1 (hr) 2020-03-06
IL268675A (en) 2019-10-31
RU2018122695A (ru) 2019-03-06
CN104202971B (zh) 2016-07-06
KR20190006029A (ko) 2019-01-16
IL233827A0 (en) 2014-09-30
CY1124361T1 (el) 2022-07-22
JP2021137030A (ja) 2021-09-16
US20170094955A1 (en) 2017-04-06
US20130212719A1 (en) 2013-08-15
US20210368751A1 (en) 2021-12-02
SMT201900685T1 (it) 2020-01-14
CA2863175A1 (en) 2013-08-08
BR112014018843A2 (pt) 2017-07-04
LT3597038T (lt) 2021-05-25
SI2809150T1 (sl) 2019-11-29
AU2017251848A1 (en) 2017-11-16
JP2015505477A (ja) 2015-02-23
RS59699B1 (sr) 2020-01-31
HUE055610T2 (hu) 2021-12-28
DK3597038T3 (da) 2021-06-28
RU2770016C2 (ru) 2022-04-14
NZ793447A (en) 2024-05-31
BR112014018843A8 (pt) 2019-01-29
EP2809150A1 (en) 2014-12-10
RU2018122695A3 (cg-RX-API-DMAC7.html) 2021-10-06
IL261280B (en) 2019-08-29
JP6698718B2 (ja) 2020-05-27
EP3597038A1 (en) 2020-01-22
SG11201404477YA (en) 2014-08-28
PT2809150T (pt) 2019-12-09

Similar Documents

Publication Publication Date Title
DK2809150T3 (da) Humaniserede mus, der udtrykker tungkæder indeholdende VL-domæner
CY2024011I1 (el) Αντισωματα anti-fcrn
DK2958938T3 (da) Mus, der eksprimerer humaniserede T-celle-co-receptorer
HUE057680T2 (hu) Korlátozott immunglobulin-nehézlánccal rendelkezõ egerek
DK2934584T3 (da) Anti-gdf15-antistoffer
HRP20181646T1 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
BR302013000789S1 (pt) Configuração aplicada em mecanismo de entrada.
BR302013000038S1 (pt) Configuração aplicada em recipiente
BR302012005543S1 (pt) Configuração aplicada em recipiente.
BR302012005545S1 (pt) Configuração aplicada em recipiente.
BR302012005547S1 (pt) Configuração aplicada em recipiente.
BR302012005542S1 (pt) Configuração aplicada em recipiente.
BR302012005494S1 (pt) Configuracao aplicada em recipiente
BR302012005544S1 (pt) Configuração aplicada em recipiente.
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
BR302013002770S1 (pt) Configuração aplicada em recipiente.
EP2825955A4 (en) INPUT DATA TYPE PROFILE
BR302012005548S1 (pt) Configuração aplicada em recipiente.
EP2877280A4 (en) Catalyst materials
EP2842163A4 (en) NONLINEAR MEMRISTORS
DK3521315T3 (da) Anti-transglutaminase-2-antistoffer
DK2828292T3 (da) Jcv-neutraliserende antistoffer
BR302012005495S1 (pt) Configuracao aplicada em recipiente
DK2935330T3 (da) Anti-notch3-antistoffer
DE102012112916A8 (de) Dosiermodul